UFC Heavyweight accepts USADA’s two-year sanction

October 20, 2017

Carlos Felipe has accepted a two-year sanction for a violation of the UFC Anti-Doping Policy.  The 22-year-old Brazilian Heavyweight’s UFC career is suspended before it ever began.

Felip tested positive for stanozolol metabolites, 16β-hydroxy-stanozolol and 3’hydroxy-stanozolol.  Per the USADA release, “Stanozolol is a non-Specified Susbstance in the category of Anabolic Agents and is prohibited at all times under the UFC Anti-Doping Policy, which has adopted the World-Anti-Doping Agency Prohibited List.  Stanozolol is sometimes used to lose fat while retaining lean body mass.

Felipe was set for his debut fight in the UFC card in Sao Paulo, Brazil on October 28th but an out of competition test on July 29th was flagged by USADA.  Prior to the UFC, he was 8-0 in his pro career.

Payout Perspective:

It’s a stiff penalty but at 22, Felipe can still return to the UFC (if they will want him) and still have a long MMA career.  Accepting the penalty likely meant that he did not have a good reason for the flagged test and it was better than attempting a lengthy legal battle.

 

 

Little Nog notified of potential USADA violation

October 19, 2017

Antonio Rogerio Nogueira has been flagged for a potential violation of the UFC Anti-Doping Policy.  The light heavyweight’s upcoming fight against Jared Cannonier has been scratched with The Killa Gorilla awaiting for a replacement.

The UFC released its standard statement regarding these matters.  A portion of which reads:

The UFC organization was notified today that the U.S. Anti-Doping Agency (USADA) has informed Antonio Rogerio Nogueira of a potential Anti-Doping Policy violation stemming from an out-of-competition sample collected on September 27, 2017. Due to the proximity of Nogueira’s upcoming scheduled bout at UFC FIGHT NIGHT: LAWLER vs. DOS ANJOS in Winnipeg, Canada on December 16, 2017 against Jared Cannonier, Nogueira has been removed from the card and the UFC is currently seeking a replacement.

Payout Perspective:

If Nogueira cannot absolve himself of this wrongdoing, it could spell the end for the 41-year-old’s career in the UFC.  This would be Nogueira’s first violation which would be a 2-year sanction unless he is able to mitigate the case with USADA.

Jesse Taylor accepts 1-year USADA suspension

October 14, 2017

USADA announced that UFC welterweight Jesse Taylor has accepted a 1-year suspension for his use of Clomiphene.  The TUF Champion will not be able to return to the Octagon until September 2018.

Via USADA news release:

Taylor, 34, tested positive for clomiphene following an out-of-competition urine test conducted on August 22, 2017. Clomiphene is a Specified Substance in the class of Hormone and Metabolic Modulators and is prohibited at all times under the UFC Anti-Doping Policy, which has adopted the World Anti-Doping Agency Prohibited List.

Clomiphene is not approved by the U.S. Food & Drug Administration (FDA) for use in the male population, as its use has not been thoroughly studied for safety and efficacy. Clomiphene also indirectly promotes the secretion of testosterone. Increasing testosterone, especially when combined with strength training, has been demonstrated to increase fat-free mass, muscle size, and strength in males, potentially leading to performance enhancement in sport.

Taylor’s one-year period of ineligibility, the highest sanction for a first offense involving a Specified Substance, began on September 13, 2017, the date his provisional suspension was imposed. As a result of his positive test, Taylor was removed from the Card for the UFC Fight Night event in Sydney, Australia, scheduled for November 18, 2017.

Payout Perspective:

Perhaps the only recourse for Taylor without expending a lot of legal costs.  Also, if he did not have a true excuse for his testing, it would only prolong the administrative battle.  It’s too bad for Taylor who just made it back into the organization.  The suspension also brings to light the issue of Clomiphene, a fertility drug for women, and the use of it by male competitors.

Lee fight removed from UFC 216

September 30, 2017

The UFC has pulled the late-announced fight of Andrea Lee-Kalindra Faria due to Lee not being in the USADA testing pool due to testing positive for diuretics in March 2016.

Due to the prior violation which she served a nine-month suspension, she would have had to undergo a minimum of six months of testing before she could fight in the UFC.

In a social media post, Lee explained that it was not the UFC’s fault “because they didn’t know about this USADA rule.”

Prior to changes to the UFC Anti-Doping Policy, an exemption could be made for fighters to receive a waiver so that they would not have to enter the testing pool within 6 months.  But since Brock Lesnar, this has changed.  This situation is a little different since Lee was previously.

Payout Perspective:

While Lee doses not blame the UFC, it’s hard not to.  Certainly, the UFC should know its own anti-doping policy and the corresponding USADA rules.  Moreover, this fight was a late add to next Saturday’s UFC 216.  It’s example of an oversight that should have not taken place as we know that Faria and Lee are probably not going to be compensated despite probably expending money to start the process of training.

USADA flags light heavyweight newcomer

September 30, 2017

Earlier this week, Azamat Murzakanov was flagged by USADA for a potential anti-doping violation.  The Russian was supposed to debut this past June but withdrew due to injury.  He now faces a 2-year suspension from the organization before event beginning.

Murzakanov was flagged for an out-of-sample competition stemming from a September 2nd test.  The light heavyweight was 7-0 prior to the UFC.

Payout Perspective:

Murzakanov was signed by the UFC but has yet to appear in the octagon.  He may never do so due to the flagged test.  He was in the testing pool since he was scheduled to fight in the UFC but had to withdraw due to injury.

Nick Roehrick accepts 1 years suspension from USADA

September 21, 2017

UFC light heavyweight Nick Roehrick has accepted a one-year suspension from the U.S. Anti-Doping Agency.  Roehrick was notified last month of a potential UFC anti-doping violation stemming from an August 8th test.

Roehrick tested positive for the presence of clomiphene, an estrogen blocker banned year-round, and its metabolite, 4-hydroxyclomiphene.  The suspension is retroactive to August 17, 2017, when the provisional suspension was imposed.

Via the USADA release:

Clomiphene is not approved by the U.S. Food & Drug Administration (FDA) for use in the male population, meaning such off-label clinical use has not been thoroughly studied for safety and efficacy. Clomiphene also indirectly promotes the secretion of testosterone. Increasing testosterone, especially when combined with strength training, has been demonstrated to increase fat-free mass, muscle size, and strength in males, potentially leading to performance enhancement in sport.

Payout Perspective:

The 30-year-old fighter had just one fight in the UFC, a loss to Jarod Cannonier at the TUF 25 Finale in July.  The maximum sentence for a first offense is 2 years so the 1 years suspension mitigates a prolonged appeal process.

Brazilian heavyweight set for UFC debut flagged by USADA

September 19, 2017

The UFC was notified that heavyweight Carlos Felipe failed a USADA out-of-competition drug test from a sample collected on July 29th.

As a result, Felipe has been taken off the UFC card in Sao Paulo, Brazil on October 28th.  He was set to face Christian Columbo.  The UFC will seek to find a replacement for Columbo.  This would have been Felipe’s debut in the UFC.  The 22-year-old is undefeated in his pro career going 8-0.

The UFC provided its standard statement upon notification from USADA:

The UFC organization was notified today that the U.S. Anti-Doping Agency (USADA) has informed Carlos Felipe of a potential Anti-Doping Policy violation stemming from an out-of-competition sample collected on July 29, 2017. Because of the proximity to Felipe’s upcoming scheduled bout in Sao Paulo, Brazil, on October 28, 2017, against Christian Columbo, Felipe has been removed from the card and UFC is currently seeking a replacement.

USADA, the independent administrator of the UFC Anti-Doping Policy, will handle the results management and appropriate adjudication of this case involving Felipe. Under the UFC Anti-Doping Policy, there is a full and fair legal process that is afforded to all athletes before any sanctions are imposed. Additional information will be provided at the appropriate time as the process moves forward.

Payout Perspective:

The Brazilian prospect was outstanding on the regional circuit but the failed test may leave him on the sidelines for a couple years if he does not have a good reason for the failed test.

Jesse Taylor notified of potential anti-doping violation

September 13, 2017

The Ultimate Fighter Redemption winner, Jesse Taylor, has been notified by USADA of a potential anti-doping violation and has been pulled from his fight at UFC Fight Night 121.

He was notified of a flagged out-of-competition sample collected on August 22nd.

Taylor was to face Belal Muhammad in Sydney on November 19th.

Payout Perspective:

This is bittersweet for many that rooted for Taylor as he was infamously kicked off of the 7th season of TUF prior to the Finale.  After one loss in the UFC, he was cut and spent most of his career traveling the world fighting in different promotions.  This TUF season, he made it back to the Finale and was successful this past July.  Now, it appears that he may be looking at another departure from the UFC based on the results of this violation.  We shall see what becomes of JT.

Jon Jones B sample comes up positive for Turinabol

September 12, 2017

ESPN reports that the “B” sample from Jon Jones’ failed drug test was positive for the banned substance Turinabol.  Jones has a right to appeal and it appears that his team is working with USADA and UFC.

USADA notified Jones of a flagged in-competition test in leadup to his fight against Daniel Cormier at UFC 214 in July.  If deemed guilty of the banned anabolic steroid he would face a maximum ban of 4 years as this is his second offense.  The first USADA test was appealed by Jones and he lost his arbitration and was banned one year from the UFC.

USADA stressed that due process should play out prior to anyone drawing conclusions.

Jones actually faces a potential sanction from the California State Athletic Commission and USADA.  He could appeal both rulings if he is not satisfied with each.

Jones denies use and is trying to determine the source of the banned substance and is looking at potential tainted supplements.

Payout Perspective:

Realistically, the B sample finding is not surprising considering that it is taken from his original sample that failed the test.  Still, Jones has options in terms of appealing the decision and/or working with USADA to trace the contents of the alleged tainted supplement.  Even if they discover the source, it is ultimately Jones’ responsibility for what goes into his body and he will suffer some sanction and away from the Octagon.  While USADA is cautioning everyone not to jump to conclusions, it’s an effort to ensure that there is no appearance of unfairness in the process.

Jon Jones USADA blood tests post-UFC 214 were negative

September 3, 2017

MMA Fighting reports that Jon Jones passed a USADA blood test post-UFC 214.  However, his urine test post-weigh-ins at UFC 214 indicated a failed test.

However, the blood test would not have been screened for Turinabol, the drug that is banned by the UFC Anti-Doping Policy.  In addition, MMA Fighting learned that Jones passed two USADA out-of-competition tests on July 6th and 7th.  One a blood and urine test and the other a urine test.

Despite the contrary results during the month of July, Jones could be facing a maximum of a 4 year banishment from the UFC.

Payout Perspective:

This case will likely face another appeal if the preliminary investigations are inconclusive.  Obviously, Jones could still be liable of taking a banned substance despite passing early out-of-competition drug tests and the in-competition blood test.  The likely hope is to mitigate the suspension.

Next Page »